Drugs / AP-325
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05160272 | Jan 2022 → Dec 2024 | type 2 diabetes mellitus | The Deutsche Diabetes Forschungsgesellschaft e.V. | Completed | No outcome recorded |
| Phase 2 | NCT04429919 | Jun 2020 → Oct 2024 | neuropathy, painful | Algiax Pharmaceuticals GmbH | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-02-04 | Algiax Pharmaceuticals GmbH | Results Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain algiax.com ↗
Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical trial evaluating AP-325 for the treatment of neuropathic pain. |
| 2023-05-30 | Algiax Pharmaceuticals GmbH | Results Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain algiax.com ↗
As part of a planned mid-enrollment interim analysis, the independent Data Monitoring Committee (DMC) recommended the continuation of the study and confirmed the absence of safety issues among the study participants. |
| 2019-12-09 | Algiax Pharmaceuticals GmbH | Regulatory Algiax Is Ready to Go Into Proof-of-Concept for AP-325 and Welcomes New Investors algiax.com ↗
The company further announced that it has filed a clinical trial application for its phase IIa clinical trial “CURE” in the EU and plans to start patient recruitment in beginning of 2020. |
| 2016-10-13 | Algiax Pharmaceuticals GmbH | Regulatory Clinical Phase Ib, Pharmacodynamic effect study algiax.com ↗
On December 10th 2015 Algiax got its approval from the German authorities (BfArM) to start the Phase Ib study entitled “Pharmacodynamic Effects of AP-325 in Healthy Male Subjects using the Intradermal (ID) Capsaicin and Pressure Pain Models”. |
| 2016-10-13 | Algiax Pharmaceuticals GmbH | Results Algiax announces positive data of Clinical Phase I algiax.com ↗
In the two clinical studies AP-325 was shown to be safe and well tolerated and the aimed exposure levels with the oral formulation have been reached. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP-325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05160272 ↗ |
| Route | Oral | “AP-325 100 mg (4 x 25 mg capsules) or Placebo (4 capsules) will be orally taken once daily in the morning before meals.” NCT04429919 ↗ |